Home » Newsletters » BioWorld Science

BioWorld Science

April 30, 2013

View Archived Issues

Epizyme to develop companion diagnostics for two novel HMT inhibitors

New software application for personalized medicine presented

Listeria-based prostate cancer vaccines developed at Aduro BioTech

Glytech designs novel cancer immunotherapeutic

Maruishi Pharmaceutical and Cara Therapeutics sign license agreement for CR-845

UCB updates pipeline progress of first quarter 2013

Humanized anti-cocaine MAb demonstrates in vivo efficacy

Angion Biomedica presents CYP17 inhibitors for the treatment of prostate cancer

AstraZeneca reports activities of first quarter 2013

MorphoSys begins phase II MOR-208 trial

Phase II results presented for solithromycin in the treatment of urogenital gonorrhea

Novel selective PI3K-beta isoform inhibitors show promising oncolytic properties

Merck & Co. discloses new JAK inhibitors

GlaxoSmithKline prepares novel fatty acid synthase inhibitors

Novartis synthesizes new histamine H3 receptor antagonists/agonists

Alimera Sciences launches Iluvien in the U.K.

Merck & Co. and Pfizer to develop and commercialize ertugliflozin

Gilead receives FDA complete response letters for elvitegravir and cobicistat

Nuvilex to advance Cell-in-a-Box technology to phase III

Addex's GABA(B) receptor PAM reduces alcohol intake in preclinical model

FDA accepts for review Octapharma's BLA for investigational 4-factor PCC octaplex

Theravance board of directors approves plan to split into two publicly traded companies

Impax Pharmaceuticals and GSK terminate IPX-066 collaboration

Veloxis Pharmaceuticals submits MAA to EMA for LCP-Tacro

Novartis initiates phase II trial of INC-280 triggering milestone payment to Incyte

SD-101 receives FDA breakthrough therapy designation for epidermolysis bullosa

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...